The Real Cost of NAD+ Therapy: IV vs Injection
Disclaimer: Compounded NAD+ is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. This article reflects my perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship.
Every conversation I have about NAD+ therapy ends up at cost. That makes sense, because cost is what determines whether someone stays on it long enough to get anything out of it.
The IV Model: $400 to $600 Per Session
Most people encounter NAD+ first as an IV infusion at a wellness clinic or IV lounge. It works. The economics are brutal.
A single session runs $400 to $600, and it is rarely one session. Loading protocols call for multiple infusions over several weeks. Each one means sitting in a clinic while the drip runs slowly, because NAD+ pushed too fast intravenously causes uncomfortable side effects. A serious protocol runs into the thousands of dollars plus hours in a chair.
I have watched the same thing happen over and over. Someone does a few sessions, feels something, then stops for three months because they cannot sustain the cost or the time. NAD+ benefit tracks consistency, and the IV model prices consistency out of reach for most people. A therapy you take sporadically is not being given a fair chance.
The Injection Model
Subcutaneous NAD+ changes the math. Our program is $139.99 for the first month, then $149 a month, self-administered at home. Different universe from $400 a session.
So what are you giving up? Peak concentration. An IV produces a high spike during the infusion. A subcutaneous injection produces a lower peak but more sustained availability across days. For most people that trade is worth making, and the reason is in how the molecule gets used.
Why Sustained Beats Peak
NAD+ is consumed continuously. The sirtuins and PARPs involved in cellular repair and energy metabolism draw on it as a substrate around the clock, not in bursts. Human studies show that raising NAD+ precursor availability produces measurable, dose-dependent increases that can be sustained with regular dosing.[1][2]
For pathways running all day, steady replenishment fits the biology better than an occasional flood followed by weeks of nothing. The injection model is cheaper, and it may also be the better match for what the molecule does.
Where IV Still Makes Sense
IV NAD+ has a role. If you want a high acute dose under clinical supervision and cost is not a constraint, it is a legitimate option. Some people prefer the supervised setting. I am not going to tell you it does not work, because it does.
For most people, though, the goal is sustained benefit over months without spending thousands of dollars and dozens of hours in clinics. That is where the injection model wins. The best therapy is the one you stay on, and cost usually decides that.
The Bottom Line
IV NAD+ runs $400 to $600 a session and often requires many of them, which puts long-term use out of reach for most people. Subcutaneous injections deliver sustained availability for a fraction of the cost in a form you administer at home. For steady benefit over time, the injection model is both the more affordable choice and the more physiologically sensible one.
To see how our NAD+ program works and what is included, visit our NAD+ therapy page.
References
1. Trammell SA, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. PubMed: 27721479
2. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PubMed: 33888596
This article reflects my personal perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult a licensed provider.
JP Rius is the founder of Precision Telemed. His perspective is shaped by the commercial, regulatory, and operational side of telehealth medicine.
